At the news
? BEARISHIMPACT 7/10 8-K filed Jul 23, 2026 at 15:13 ET
UTMD reported Q2 2026 revenue of $8.5M, down 14.3% YoY, and EPS of $0.844, down 10.1% YoY, reflecting the continued loss of its two largest customers (PendoTECH and China distributor). Management lowered full-year 2026 revenue guidance to a 10-13% decline from prior expectations of flat sales, as new product sales to biopharma customers have been slower than anticipated. The balance sheet remains debt-free with $87.5M cash, but the top-line trajectory and guidance cut signal ongoing headwinds.
- Q2 2026 revenue fell 14.3% to $8.53M vs $9.95M in Q2 2025; EPS declined 10.1% to $0.844 from $0.939
- Full-year 2026 revenue guidance lowered to a 10-13% decline (from prior expectation of flat vs 2025) due to slower-than-expected new product sales
- Loss of two former largest customers (PendoTECH OEM and China distributor) accounted for 75% of the Q2 revenue decline
- Litigation expense guidance raised: 2026 now expected to be less than $1.6M (vs $1.355M in 2025), reversing prior expectation of a decline
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access